Ryan M. Byrne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ryan M. Byrne has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
- Philip David Dunne
Queens University Belfast, Patrick G Johnston Centre for Cancer Research, Belfast, UK
119 shared publications - Owen James Sansom
School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
116 shared publications - Simon J. Leedham
Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
116 shared publications - Hayley L. Belnoue-Davis
Centre for Human Genetics, University of Oxford, Oxford, UK
94 shared publications - Kathryn Gilroy
Cancer Research UK Scotland Institute, Glasgow, United Kingdom
94 shared publications - Rachel A. Ridgway
Cancer Research UK Scotland Institute, Glasgow, UK
94 shared publications
Latest Publications
- Open Access
- 26 May 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Viral mimicry redirects immunosuppressed colorectal tumour landscapes towards a proinflammatory and CMS1-like regenerative state
In colorectal cancer (CRC), tumours classified as consensus molecular subtype 4 (CMS4) have the worst prognosis and derive negligible benefit from chemotherapy. We previously described how repressed interferon-related signalling is associated with increased relapse in CMS4 tumours. Although the viral mimetic polyinosinic:polycytidylic acid, poly(I:C), can reduce liver metastasis in vivo, the initial phenotypic changes that underpin its anti-metastatic response remain poorly described, particularly in the immunosuppressed CMS4 tumour microenvironment. Here we characterise lineage-specific anti-metastatic responses induced by poly(I:C), including acute macrophage polarisation and a novel CMS1-like regenerative stem cell state, which drive pro-inflammatory microenvironmental changes in CRC. These insights enabled the development of tractable biomarkers that identify an “immune-warm” patient subset most likely to respond to poly(I:C), enriched for mismatch-repair proficient (pMMR), anti-inflammatory macrophages and CMS4-like features. The viral mimetic poly(I:C) offers a tailored treatment option for poor-prognostic tumours, by reprogramming stem cell states and activation of an innate-adaptive anti-metastatic response.
- 26 May 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessViral mimicry redirects immunosuppressed colorectal tumour landscapes towards a proinflammatory and CMS1-like regenerative state
In colorectal cancer (CRC), tumours classified as consensus molecular subtype 4 (CMS4) have the worst prognosis and derive negligible benefit from chemotherapy. We previously described how repressed interferon-related signalling is associated with increased relapse in CMS4 tumours. Although the viral mimetic polyinosinic:polycytidylic acid, poly(I:C), can reduce liver metastasis in vivo, the initial phenotypic changes that underpin its anti-metastatic response remain poorly described, particularly in the immunosuppressed CMS4 tumour microenvironment. Here we characterise lineage-specific anti-metastatic responses induced by poly(I:C), including acute macrophage polarisation and a novel CMS1-like regenerative stem cell state, which drive pro-inflammatory microenvironmental changes in CRC. These insights enabled the development of tractable biomarkers that identify an “immune-warm” patient subset most likely to respond to poly(I:C), enriched for mismatch-repair proficient (pMMR), anti-inflammatory macrophages and CMS4-like features. The viral mimetic poly(I:C) offers a tailored treatment option for poor-prognostic tumours, by reprogramming stem cell states and activation of an innate-adaptive anti-metastatic response.
- Open Access
Phenotype-dependent subtyping exposes high MYC activity as a targetable dependency in LuAd
C-MYC (MYC) occupies a critical nexus of oncogenic signalling and deregulated expression of MYC is widespread across most human cancer types, suggesting that MYC should be an attractive target for therapeutic intervention. Although 30-40% of human Non-Small Cell lung cancers show low level amplification of c-MYC and genetic evidence has shown that c-Myc is a key downstream effector of KRas-driven lung tumourigenesis in mouse models, the functional contribution of MYC to human lung cancer remains unclear. We applied a phenotype-based classifier to the TCGA Lung Adenocarcinoma (LuAd) cohort and found that high MYC transcriptional activity identifies a subset of LuAd with significantly reduced survival. Application of the same methodology to a panel of genetically engineered mouse models identified multiple genotypes that give rise to the high MYC activity phenotype, disease positioning such models as reflective of a distinct subset of human LuAd. We show that high MYC activity predicts sensitivity to a small molecule dual-inhibitor of the MYC co-factors, EZH2 and G9A, HKMTi-1-005, and that treatment with HKMTi-1-005 strongly reduced MYC protein expression, induced B cell-mediated immune surveillance and suppressed growth of autochthonous KRasG12D-driven lung tumours. Statement of significance This work establishes the principle of indirectly targeting MYC in LuAd, via inhibition of associated enzymatic cofactors, EZH2 and G9A, and identifies a large subset of aggressive human LuAd with a high MYC activity signature that may benefit from this approach.
Open AccessPhenotype-dependent subtyping exposes high MYC activity as a targetable dependency in LuAd
C-MYC (MYC) occupies a critical nexus of oncogenic signalling and deregulated expression of MYC is widespread across most human cancer types, suggesting that MYC should be an attractive target for therapeutic intervention. Although 30-40% of human Non-Small Cell lung cancers show low level amplification of c-MYC and genetic evidence has shown that c-Myc is a key downstream effector of KRas-driven lung tumourigenesis in mouse models, the functional contribution of MYC to human lung cancer remains unclear. We applied a phenotype-based classifier to the TCGA Lung Adenocarcinoma (LuAd) cohort and found that high MYC transcriptional activity identifies a subset of LuAd with significantly reduced survival. Application of the same methodology to a panel of genetically engineered mouse models identified multiple genotypes that give rise to the high MYC activity phenotype, disease positioning such models as reflective of a distinct subset of human LuAd. We show that high MYC activity predicts sensitivity to a small molecule dual-inhibitor of the MYC co-factors, EZH2 and G9A, HKMTi-1-005, and that treatment with HKMTi-1-005 strongly reduced MYC protein expression, induced B cell-mediated immune surveillance and suppressed growth of autochthonous KRasG12D-driven lung tumours. Statement of significance This work establishes the principle of indirectly targeting MYC in LuAd, via inhibition of associated enzymatic cofactors, EZH2 and G9A, and identifies a large subset of aggressive human LuAd with a high MYC activity signature that may benefit from this approach.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Identification of a WNT responsive element (WRE) in the HNF4G genomic locus.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Identification of a WNT responsive element (WRE) in the HNF4G genomic locus.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Disruption of WNT gradient in normal intestinal villi reduces gamma delta T cells
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Disruption of WNT gradient in normal intestinal villi reduces gamma delta T cells
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Clinicopathological characteristics of colon cancer patient cohorts.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Clinicopathological characteristics of colon cancer patient cohorts.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
WNT expression is independent of BTN3A1 and BTN2A1
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
WNT expression is independent of BTN3A1 and BTN2A1
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Correlation between gut-specific transcription factors, gamma delta T cell density and BTNL genes in human tumors
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Correlation between gut-specific transcription factors, gamma delta T cell density and BTNL genes in human tumors
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Deletion of Apc in organoids increases WNT target genes
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Deletion of Apc in organoids increases WNT target genes
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Impact of Btnl1 and Btnl6 expression on Vgamma7+ cells and the tumor microenvironment
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from β-Catenin Drives Butyrophilin-like Molecule Loss and γδ T-cell Exclusion in Colon Cancer
Impact of Btnl1 and Btnl6 expression on Vgamma7+ cells and the tumor microenvironment